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Abstract 
Clinical treatment of heart failure is still not fully solved. A novel class of agents, the myosin 
motor activators, acts directly on cardiac myosin resulting in an increased force generation 
and prolongation of contraction. Omecamtiv mecarbil, the lead molecule of this group, is 
now in human 3 phase displaying promising clinical performance. However, omecamtiv 
mecarbil is not selective to myosin, since it readily binds to and activates cardiac ryanodine 
receptors (RyR-2), an effect that may cause complications is case of overdose. In this study, 
in silico analysis was performed to investigate the docking of omecamtiv mecarbil and other 
structural analogues to cardiac myosin heavy chain and RyR-2 in order to select the structure 
which has a higher selectivity to myosin over RyR-2. In silico docking studies revealed that 
omecamtiv mecarbil has comparable affinity to myosin and RyR-2: the respective Kd values 
are 0.60 and 0.87 µM. Another compound CK-1032100 has much lower affinity to RyR-2 
than omecamtiv mecarbil, while it still has a moderate affinity to myosin. It was concluded 
that further research starting from the chemical structure of CK-1032100 may result a better 
myosin activator burdened probably less by the RyR-2 binding side effect. It also is possible, 
however, that the selectivity of omecamtiv mecarbil to myosin over RyR-2 cannot be 
substantially improved, because similar moieties seem to be responsible for the high affinity 
to both myosin and RyR-2. 
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Introduction  
 
Heart failure is a dominant factor of mortality in Europe and North America with 
progressively increasing prevalence. The failing heart is unable to produce the cardiac 
output required for sufficient perfusion of the body. In spite of the various inotropic 
strategies developed in the past, the clinical treatment of heart failure is still problematic. 
All the currently used positive inotropic agents, including the application of cardiac 
glycosides, -adrenergic agonists, phosphodiesterase inhibitors and Ca2+ sensitizers, are 
burdened by more or less serious side-effects. Some of them, like cardiac glycosides, -
adrenergic agonists and phosphodiesterase inhibitors, are proarrhythmic due to the 
elevated cAMP level and the concomitant Ca
2+
 overload, which are known to cause early 
and late afterdepolarizations and increase cardiac oxygen consumption (January and 
Fozzard 1988; Priori and Corr 1990; January and Riddle 1990; Fozzard 1992; Tweedie et 
al. 2000; Ardehali et al. 2012). Ca
2+
 sensitizers are neither proarrhythmic, nor they 
increase cardiac oxygen demand, but may cause diastolic stiffness resulting in decreased 
ventricular filling (Lehmann et al. 2003; Endoh 2008). 
 Due to the above mentioned shortcomings a new generation of inotropes has 
recently been developed: the group of myosin motor activators, agents enhancing systolic 
force by direct modification of the actin-myosin interaction (Endoh 2008; Sun et al. 2008; 
Solaro 2009; Solaro 2010; Liu et al. 2015). Specifically, these compounds increase 
cardiac contractility by binding to the heavy chain of the cardiac myosin molecule, like 
omecamtiv mecarbil, the lead molecule of this group. The positive inotropic effect of 
omecamtiv mecarbil is based on its selective association to the S1 domain of the heavy 
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chain of cardiac -myosin at the site where the converter domain and the relay helix 
converge in the vicinity of the force-generating lever arm. The consecutive 
conformational change in the nucleotide-binding domain of myosin results in enhanced 
ATPase activity and also in robust alterations of the mechanical properties of myosin 
head (Malik and Morgan 2011). Due to the allosteric modulation of the nucleotide-
binding domain, the inorganic phosphate production, which is the rate-limiting step of the 
actomyosin cycle, is accelerated by omecamtiv mecarbil. As a consequence, the transition 
rate between the weakly bound and the strongly bound configurations of the actin-myosin 
dimer also accelerates (Malik et al. 2011). The resultant higher number of force-
generating cross-bridges increases the amplitude and lengthens the duration of 
contractions (Malik et al. 2011; Teerlink 2009; Mamidi et al. 2015; Winkelmann et al. 
2015; Swenson et al. 2017). 
Clinically, promising results have been obtained with omecamtiv mecarbil. 
Several studies, including phase-1, phase-2 and phase-3 ones, indicated that left 
ventricular systolic function was improved significantly by omecamtiv mecarbil in a 
dose-dependent manner. This included the elevation of stroke volume and left ventricular 
ejection time, associated with reduction of end-systolic and end-diastolic diameters of the 
ventricles (Cleland 2011; Teerlink et al. 2011; Teerlink et al. 2016a; Teerlink et al. 
2016b; Galactic-HF Study). These beneficial effects were evident at therapeutically 
relevant concentrations (typically in the submicromolar range), however, higher, 
supratherapeutic concentrations (in the micromolar range) caused occasionally 
difficulties with ventricular filling and myocardial ischemia developing on the basis of 
the lengthened duration of systole on the expense of diastole (Cleland et al. 2011; 
Teerlink et al. 2011). 
Since the compromised ventricular filling may also be related to altered function 
of the sarcoplasmic reticulum, the effect of omecamtiv mecarbil on canine RyR-2 was 
studied by monitoring the electrical activity of single RyR-2 channels incorporated into 
planar lipid bilayers (Nánási et al. 2017). Omecamtiv mecarbil significantly and 
reversibly increased the open probability and opening frequency of RyR-2 from the 
concentration of 1 µM. Accordingly, the mean closed time was reduced while the mean 
open time increased, indicating that increased open probability was mainly due to the 
increased frequency of opening induced by omecamtiv mecarbil. In addition, this RyR-2 
activating effect of the agent was more prominent at low, close to diastolic intracellular 
Ca
2+
 levels. Pharmacological activation of the RyR-2 may be expected to enhance 
contractility - provided that this effect is more pronounced during systole than diastole. 
Experimentally the opposite was observed, i.e. the stimulatory effect of omecamtiv 
mecarbil on RyR-2 was the strongest at diastolic Ca
2+
 levels (Nánási et al. 2017). Indeed, 
diastolic shortening of single canine myocytes was more increased than systolic 
shortening in the presence of 10 µM omecamtiv mecarbil, although this was not 
accompanied with the expected marked increases in cytosolic Ca
2+
 levels (Horváth et al. 
2017). 
Based on these results, the direct stimulatory action of omecamtiv mecarbil on 
RyR-2 has to be taken into account when discussing the mechanism of action and the 
potential effects or side effects of the compound. Or alternatively, the structure has to be 
modified in order to minimize its RyR-2 stimulating activity. This was attempted in the 
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present study by performing in silico docking experiments with omecamtiv mecarbil and 
some related compounds on cardiac myosin and RyR-2. 
 
Mehods 
 
The results overviewed in the introduction made it clear that canine RyR-2 binds omecamtiv 
mecarbil with a reasonably high affinity. In order to find the binding site for omecamtiv 
mecarbil on the surface of RyR-2, the cryo-electron microscopy structure of the open-pore 
RyR-2 was downloaded from the PDB database; PDB ID: 5goa (Peng et al. 2016). Since 
RyR-2 is one of the largest ion channels, the downloaded structure was further simplified to 
be suitable for efficient docking experiments. In absence of information on how omecamtiv 
mecarbil can associate with RyR-2, first a “blind-docking” protocol was chosen, i.e. the 
whole protein surface was considered as a potential target for the drug. The rigid receptor-
flexible ligand docking model was performed by means of VINA (Trott and Olson 2010) 
using default parameters as implemented in the YASARA software (Krieger 2014). 
 
Results 
 
Excluding those poses which are situated inside the membrane and others which are on the 
surface of the membrane, the area containing the most probable binding sites for omecamtiv 
mecarbil are presented in Fig. 1.A, and a magnified view of the residues on this surface 
together with the binding pose of omecamtiv mecarbil are shown in Fig. 1.B. According to 
the results of docking, the role of residues S4154, S4156, Q4202, W4646, I4927 and N4928 
have to be emphasized for the proposed binding pose for omecamtiv mecarbil. It is likely that 
hydrophobic interactions are intimately involved in binding of the agent. Further support is 
given to this binding pose by the good agreement between the presently estimated Kd of 0.87 
µM and the experimentally determined Kd value of 1.6 µM (Malik and Morgan 2011). Here 
is to be mentioned that our docking studies have some limitations, since the resolution of the 
RyR-2 protein structure is not optimal for high precision docking. In addition, the protein 
structure downloaded has many unresolved regions and the probably highly variable 
positions of these regions may influence the results obtained. However, bearing these 
limitations in mind, we believe that these docking studies can be regarded as a first attempt to 
shed light on the possible interactions between omecamtiv mecarbil and the cardiac 
ryanodine receptor. 
One possible way to get rid of - or at least to minimize - the effect of myosin motor 
activators on RyR-2, is to find the optimal structure which is bound less to RyR-2, while is 
still bound relatively well to its therapeutic binding site, i.e. to the human beta-cardiac 
myosin motor domain receptor; PDB ID: 4pa0 (Winkelmann et al. 2015). Therefore 
omecamtiv mecarbil, together with its five ancestors shown in Fig. 2, were docked to both 
RyR-2 and the beta-cardiac myosin to determine their affinities simultaneously to the two 
binding sites. The first structure reported to enhance the ATPase activity of myosin was CK-
0156636. Water solubility was improved and protein binding was reduced by substitution of 
the nitrate group for fluorine in the successor, CK-1032100. The first agent found to increase 
fractional shortening of cardiac muscle was CK-1122534, but its selectivity was insufficient 
due to interactions with ATP-sensitive K
+
 channels. In the next step CK-1213296 was 
developed. This compound failed to interfere with cardiac ion channels but suppressed the 
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activity of CYP 1A2. All these unfavorable effects were eliminated from CK-1317138, while 
the optimal in vitro effects were obtained with omecamtiv mecarbil (CK-1827452), which 
was more effective than its ancestor, by one order of magnitude (Morgan et al. 2010; 
Teerlink et al. 2011; Aksel et al. 2015). Docking all these structures to RyR-2 and myosin 
was performed. In the case of myosin, the local docking/refinement protocol could be applied 
with default parameters, since here the binding site was well defined. The results are 
presented in Table 1. Only one compound, CK-1032100 was found to have a sufficiently low 
affinity to RyR-2 and a moderately high affinity to myosin - which is still too low for 
sufficient activation of the myosin heavy chain.  
Since the two compounds, CK-0156636 and CK-1032100, both having unsubstituted 
nitrogen in the aromatic Ring 1, had the lowest affinity (largest Kd values) to RyR-2, our 
analysis suggests that substitution of nitrogen, and the consequent de-aromatization of Ring 
1, may be responsible for the increased affinity to RyR-2. This finding may initiate a new 
tailoring strategy for modification of Ring 1 in order to lowering the affinity of the 
compound to RyR-2. 
 
Discussion 
 
In this paper the mechanism of action of myosin motor activators, including the lead 
molecule of omecamtiv mecarbil, has been discussed in details. This new group of agents 
was designed to support the cardiac function of patients with heart failure by utilizing their 
unique ability to increase the number of force generating actomyosin cross bridges. The 
molecule is currently in human phase 3, its further development is apparently promising 
(Meijs et al. 2012; Garg and Frishman 2013; Liu et al. 2016; Moin et al. 2016). On the other 
hand, omecamtiv mecarbil is not so selective as believed earlier because it activates RyR-2 
receptors as well (Nánási et al. 2017). In the present study an attempt was made to identify 
the underlying binding site using in silico analysis and a possible direction of modification of 
the chemical structure has been proposed in order to increase its selectivity to myosin. It must 
be emphasized that our results may be considered only as suggestions regarding the direction 
of possible chemical modifications because of the limitations mentioned before. An 
alternative possibility that omecamtiv mecarbil can not be made much more selective to 
myosin can not be ruled out either, since similar structures seem to be responsible for the 
high affinity to myosin as well as to RyR-2. In this case the RyR-2 activating effect of 
omecamtiv mecarbil has to be considered as an unavoidable side-effect of the drug. Further 
studies, based on the proposed outlines of the structure-activity relationship (e.g. 
development and probing compounds with aromatic Ring 1), are required to clarify this 
point. 
Regarding the clinical application of omecamtiv mecarbil in the future, extra care has 
to be taken in cases of overdose since supratherapeutic concentrations of omecamtiv mecarbil 
may cause complications due to activation of cardiac ryanodine receptors. Although cytosolic 
Ca
2+
 concentrations were not increased significantly by omecamtiv mecarbil (only a small, 
non significant elevation in the amplitude of the Ca
2+
 transient could be observed, Horváth et 
al. 2017), this does not exclude the possibility of Ca
2+
 leak from the SR. Ca
2+
-sensitive 
fluorescent dyes monitor cytosolic Ca
2+
 mainly in the bulk phase, while the Ca
2+
 leak is 
directed into the fuzzy space, from where it can be eliminated rapidly. The enhancement of 
the main Ca
2+
-eliminating mechanism, the forward mode Na
+
/Ca
2+
 exchange, may generate 
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an inward current which was shown to be proarrhythmic (January and Riddle 1990). In 
addition, the diastolic Ca
2+
 leak may also contribute to the development of diastolic stiffness 
combined with angina, observed in some patients with omecamtiv mecarbil overdose. It must 
be born in mind that all these complications are anticipated only in cases of overdose 
intoxication when the plasma concentration of omecamtiv mecarbil reaches highly 
supratherapeutic levels. 
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Table 1. 
 
Affinity of omecamtiv mecarbil (OM) and its ancestors to the cardiac ryanodine receptor 
(RyR-2) and myosin heavy chain. Dissociation constants (Kd) and binding energies were 
obtained by docking the compounds to RyR-2 and myosin. 
 
    RyR-2   Myosin 
Binding Kd  Binding Kd 
   energy  energy 
(kcal/mol) (µM)  (kcal/mol) (µM) 
 
CK-0156636  6.28  24.93  6.74  11.43 
CK-1032100  6.27  25.35  7.30  4.49 
CK-1122534  8.59  0.50  6.74  11.39 
CK-1213296  7.83  1.83  6.92  8.52 
CK-1317138  7.70  2.26  5.82  53.82 
CK-1827452 (OM) 8.27  0.87  8.49  0.60 
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Figure legends 
 
Fig. 1. A: The RyR-2 receptor model used for docking and the position of omecamtiv 
mecarbil on its surface. B: A close view of omecamtiv mecarbil in its most likely docked 
pose obtained from docking experiments. Residues likely involved in omecamtiv 
mecarbil binding are marked individually. The figures were prepared using the YASARA 
software. 
 
Fig. 2. Chemical structure of omecamtiv mecarbil (methyl 4-[(2-fluoro-3-{[N-(6-
methylpyridine-3-yl)carbamoyl]amino}phenyl)methyl] piperazine-1-carboxylate), known 
also as CK-1827452, and its ancestors showing the steps of drug development. Structural 
modifications are indicated by circles. 
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